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Abstract
 
The distribution of secretory leukocyte protease inhibitor (SLPI) at entry portals indicates its in-
volvement in defending the host from pathogens, consistent with the ability of SLPI to inhibit
human immunodeficiency virus (HIV)-1 infection by an unknown mechanism. We now dem-
onstrate that SLPI binds to the membrane of human macrophages through the phospholipid-
binding protein, annexin II. Based on the recent identification of human cell membrane phos-
phatidylserine (PS) in the outer coat of HIV-1, we define a novel role for annexin II, a PS-binding
moiety, as a cellular cofactor supporting macrophage HIV-1 infection. Moreover, this HIV-1
PS interaction with annexin II can be disrupted by SLPI or other annexin II–specific inhibitors.
The PS–annexin II connection may represent a new target to prevent HIV-1 infection.
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Introduction
 
Secretory leukocyte protease inhibitor (SLPI), originally
identified as a serine protease inhibitor at portals of patho-
gen entry and in mucosal fluids (1), has more recently been
associated with multiple functions relevant to innate host
defense (2–9). One of the first novel non-antiprotease
functions identified for SLPI was its ability to inhibit HIV-1
infection of macrophages, which appeared to be effected
through interaction with unidentified host cell molecules
and not the virus (2, 3). In addition to CD4, macrophages
express CCR5 and CXCR4 that function as HIV-1 envelope
gp120 coreceptors (10), and once colonized by HIV-1, can
function as stable reservoirs of the virus, thereby facilitating
transmission of HIV-1 to CD4
 
  
 
lymphocytes (11, 12). Per-
sistent evidence favors the existence of additional cofactors
for binding and/or entry of HIV-1, including components
of the host cell membrane acquired during viral budding
(13). Among these host-derived constituents in the viral
envelope is the phospholipid, phosphatidylserine (PS; refer-
ence 14), which predicts a potential interactive molecule
on the receptive host cell that may facilitate virus binding,
entry, and/or fusion.
Despite tremendous efforts over the last decade, a cell
surface receptor for SLPI has remained elusive. To deci-
pher the mechanisms by which SLPI regulates target cell
functions independent of protease inhibition, we searched
for a membrane-binding protein/receptor for SLPI on
mononuclear phagocytes that are susceptible to its antiin-
flammatory and antiviral activities (2–4, 6–8). In this study,
we document that SLPI binding to the macrophage cell
membrane involves annexin II. Annexin II is a member of
the larger annexin gene family and contains a variable
NH
 
2
 
-terminal tail, a COOH-terminal region with heparin
and plasminogen-binding sites, and the core domain,
which includes binding sites for Ca
 
2
 
 
 
, phospholipids, and
F-actin (15–18). Characterized by a highly conserved set of
 
 
 
-helical repeats that mediate membrane binding, annexin
II exists as a monomer (p36) or a heterotetramer con-
structed of two p36 and two p11(S100A10) subunits, and
traffics to the cell surface by an unknown mechanism (18).
Although implicated in exocytosis and endocytosis path-
ways, as well as in ion channel activity and stimulation of
DNA replication (17), annexin II has not previously been
linked to HIV-1. Nonetheless, annexin II has recently been
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identified as a receptor for CMV (19) and respiratory syn-
cytial virus (20), prompting our exploration of a potential
role for annexin II in HIV-1 infection and as a conduit for
inhibition by SLPI and/or other targeted interventions in
the battle against AIDS.
 
Materials and Methods
 
Isolation of Monocytes.
 
Human PBMCs, obtained by leuka-
pheresis of healthy volunteers (Dept. of Transfusion Medicine,
NIH), were diluted in endotoxin-free PBS without Ca
 
2
 
  
 
and
Mg
 
2
 
  
 
for density sedimentation. Monocytes and T cells were pu-
rified by elutriation (2, 3). Monocytes were cultured in DMEM
(BioWhittaker) supplemented with 2 mM 
 
l
 
-glutamine and 10
 
 
 
g/ml gentamicin. For monocyte-derived macrophages, mono-
cytes were adhered and cultured in supplemented DMEM and
10% FBS for 7–10 d. The human myelomonocytic U937 cell line
(American Type Culture Collection) was cultured in RPMI 1640
medium containing 2 mM 
 
l
 
-glutamine, 50 IU/ml penicillin, 50
 
 
 
g/ml streptomycin, and 10% FBS at 37
 
 
 
C in a humidified at-
mosphere of 5% CO
 
2
 
.
 
Biotinylation of Recombinant Human SLPI (rhSLPI).
 
rhSLPI
(R&D Systems) was biotinylated with EZ-Link Sulfo-NHS-LC-
biotin (Pierce Chemical Co.). rhSLPI and NHS-LC-biotin were
diluted in PBS on ice and incubated for 2 h. To remove unreacted
biotin, the mixture was centrifuged using centricon filters (YM-3;
Millipore). After centrifugation, the sample was diluted in PBS,
centrifuged twice, and the biotinylated protein concentration was
determined (Bio-Rad Laboratories).
 
Flow Cytometry.
 
Cells were incubated with 10 
 
 
 
g/ml rhSLPI
for 60 min in DMEM at 37
 
 
 
C, washed, and stained using 1 
 
 
 
g/
ml of goat polyclonal anti-SLPI (R&D Systems) for 30 min at
4
 
 
 
C. Antibody-treated cells were rinsed, incubated with FITC-
conjugated secondary antibody (donkey anti–goat; Jackson Im-
munoResearch Laboratories), washed, and fixed in 2% parafor-
maldehyde (Electron Microscopy Sciences) before analysis on a
FACSCalibur flow cytometer (Becton Dickinson) using CELL-
Quest software (21, 22). Additionally, cells were incubated with
1 
 
 
 
g/ml of biotinylated rhSLPI for indicated intervals, washed,
and then treated with streptavidin-FITC (Pierce Chemical Co.)
in staining buffer (PBS containing 0.5% BSA and 0.01% sodium
azide). For additional staining, elutriated T cells, monocytes, and
monocyte-derived macrophages detached from plastic with cell
dissociation buffer (Invitrogen) were suspended in PBS with 2%
FBS and stained with 10 
 
 
 
g/ml of polyclonal goat annexin II
(Santa Cruz Biotechnology, Inc.) and a secondary antibody
(donkey anti–goat FITC; Jackson ImmunoResearch Laborato-
ries). Single and double labeling with PE-CD14, FITC-CCR5,
PE-CD11c, or PE-CD4 (BD Biosciences) confirmed cell speci-
ficity in flow cytometry analysis.
 
Fluorescence Microscopy.
 
10
 
6 
 
cells cultured in four-chamber
glass slides (Nunc) were incubated with biotinylated rhSLPI from
5 s to 60 min at 37
 
 
 
C, washed, and neutravidin-FITC (Jackson
ImmunoResearch Laboratories) in PBS was added for 30 min at
4
 
 
 
C. Slides were rinsed, fixed in 2% paraformaldehyde, incubated
with propidium iodide (Sigma-Aldrich) for 5 min, rinsed, and
mounted with SlowFade (Southern Biotechnology Associates,
Inc.) for fluorescence microscopy. In additional experiments,
monocytes were plated on glass coverslips in 24-well plates (2 
 
 
 
10
 
6 
 
per well) and cultured as described above for 7–10 d. Before
staining, coverslips were washed in PBS, fixed in 2% paraformal-
dehyde for 30 min, and then incubated in 100 mM glycine in PBS
at room temperature for 20 min. Cells were rinsed in PBS, meth-
anol permeabilized at 
 
 
 
20
 
 
 
C for 5 min, and then blocked in 10%
donkey serum for 30 min. 2 
 
 
 
g/ml of primary antibody (mouse
anti–annexin II; Transduction Labs) was added in 2% donkey se-
rum in PBS, washed, and incubated for 1 h in 20 
 
 
 
g/ml Alexa
647–conjugated donkey anti–mouse (Molecular Probes). Cells
were washed twice in PBS, twice in dH
 
2
 
O, mounted using Fluor-
mount G (Electron Microscopy Services), and visualized using the
PerkinElmer UltraView LCI confocal system with a Nikon
Eclipse microscope. For phagocytosis of apoptotic cells, Jurkat
cells (200,000/ml) were treated with 0.2 
 
 
 
M staurosporine at
37
 
 
 
C for 7 h, washed, stained with 1 
 
 
 
M carboxyfluorescein diac-
etate succinimidyl ester (Sigma-Aldrich) in PBS for 20 min, and
washed before being added (4 
 
  
 
10
 
6
 
) to macrophages on cover-
slips. After 10 min at 37
 
 
 
C, the coverslips were vigorously
washed, fixed, and stained for annexin II as described above.
 
Immunoprecipitation and Western Blot.
 
200–300 
 
  
 
10
 
6 
 
mono-
cytes in suspension or 7–10-d adhered macrophages were washed
with PBS. Cell pellets were collected and incubated in sucrose ly-
sis buffer (250 mM sucrose with complete EDTA-free protease
inhibitor cocktail; Roche Applied Science) on ice, and then soni-
cated. The nuclear fractions were discarded after centrifugation
(2,000 rpm at 4
 
 
 
C) and the membrane fraction was resuspended
in PBS with protease inhibitors, centrifuged (14,000 rpm for 30
min), and then the cytosol fraction was discarded. Membrane
protein fractions were sonicated and proteins were quantitated
(Bio-Rad Laboratories) before being precleared with normal IgG
and UltraLink immobilized protein A/G beads (Pierce Chemical
Co.) with rotation (30 min at 4
 
 
 
C). The beads were pelleted
(2,500 rpm) for 5 min at 4
 
 
 
C. The supernatant was incubated
with rhSLPI for 5–10 min on ice and rotated for 1–2 h at 4
 
 
 
C
with polyclonal goat anti-rhSLPI (Santa Cruz Biotechnology,
Inc.), mouse monoclonal anti–annexin II (IgG1; BD Biosciences),
or anti-actin (IgG1; Santa Cruz Biotechnology, Inc.). UltraLink
beads were added to this mixture and rotated overnight at 4
 
 
 
C.
The immunoprecipitates were boiled in reducing SDS-PAGE
sample buffer after PBS wash and subjected to SDS-PAGE in
Tris-glycine gels. For Western blot, the proteins were transferred
to a nitrocellulose membrane and probed with 1 
 
 
 
g/ml of poly-
clonal anti-SLPI (Santa Cruz Biotechnology, Inc.), anti–annexin
II, anti-actin, or anti–
 
 
 
-tubulin (Sigma-Aldrich) followed by an
appropriate horseradish peroxidase–conjugated secondary anti-
body (Santa Cruz Biotechnology, Inc.). Chemiluminescent signal
was detected using the Supersignal West Pico system (Pierce
Chemical Co.). Whole cell lysates from A431 or Jurkat cell lines
were obtained from BD Transduction Laboratories.
 
Nano-Capillary HPLC Ion Trap Mass Spectrometry (LC-MS/MS).
 
Membrane protein fractions from monocyte (2–10 
 
  
 
10
 
9
 
) or
macrophage (2–10 
 
  
 
10
 
9
 
) coimmunoprecipitations were pooled
and separated on SDS-PAGE. The gels were stained with col-
loidal blue, destained, photographed, and the desired protein
band(s) was marked before storage at 4
 
 
 
C. The gels were ana-
lyzed with LC-MS/MS of in-gel tryptic digests for subsequent
protein identification by database searching (Wistar Institute).
The output from the National Center for Biotechnology Infor-
mation and nonredundant database search using SEQUEST con-
sists of peptide sequences matched to protein(s) in the database
searched by correlated predicted and observed peptide fragmenta-
tion patterns.
 
RT-PCR.
 
Total cellular RNA was extracted using the
RNeasy minikit (QIAGEN). 2 
 
 
 
g RNA was reverse transcribed
by oligodeoxythymidylic acid primer (Promega) and the resulting
1 
 
 
 
l cDNA was amplified by PCR. The primer sets for annexin 
Ma et al.
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II were ATGTCTACTGTTCACGAAATC (sense) and AAT-
GAGAGAGTCCTCGTCGG (antisense). For normalization,
GAPDH primer sets were GTGAAGGTCGGGAGTCAACG-
GATTT (sense) and CACAGTCTTCTGGGTGGCAGTGAT
(antisense). PCR was performed using 1.5 mM MgCl
 
2
 
, 200 
 
 
 
M
deoxynucleoside triphosphates, 10 pmol of each primer, and 1 U
Taq polymerase (Invitrogen). cDNA was amplified for 25 cycles
with the following settings: 94
 
 
 
C for 30 s, 55
 
 
 
C for 30 s, and
68
 
 
 
C for 30 s.
 
Small Interfering RNA (siRNA) Inhibition of Annexin II.
 
An-
nexin II siRNA 1 and 2 were synthesized based on the sequence
r(GCACUGAAGUCAGCCUUAUUU)/r(AUAAGGCUG-
ACUUCAGUGCUG) and r(CGGUGAUUUUGGGCCUAU-
UUU)/r(AAUAGGCCCAAAAUCACCGUC; QIAGEN). An
unrelated control siRNA was also purchased from QIAGEN.
SiRNA was transfected into monocytes using the Amaxa Human
Dendritic Cell Nucleofector kit following the protocol for nucle-
ofection of suspension cells. The cells were incubated 6 d before
analysis of annexin protein by Western blot and infection with
HIV-1.
 
HIV-1 Infection.
 
Adherent macrophages were infected with
R5 HIV-1
 
BAL 
 
grown in primary human macrophage cultures (50
 
 
 
l TCID
 
50 
 
  
 
10
 
4
 
/ml; Advanced Biotechnologies Inc.) for 2 h at
37
 
 
 
C, unbound virus was washed away, and the cells were cul-
tured in DMEM containing 10% FCS at 37
 
 
 
C for 1–14 d (2, 3).
One half of the supernatant was collected every 2–3 d and re-
placed with fresh medium. Supernatants were tested for HIV-1
p24 antigen by ELISA (PerkinElmer). For preparation of addi-
tional isolates, 60 
 
  
 
10
 
6 
 
PHA-activated PBMCs were pelleted for
10 min at 1,500 rpm in a 15-ml conical tube, the supernatant was
removed, and 1 ml of virus seed stock (HIV-1 JRCSF, ADA, and
primary isolate Clade B 92US712; NIH AIDS Research and
Reference Reagent Program) was added to the target cells with
gentle mixing. After 1–2 h of incubation, the cell/virus mixture
was diluted to 30 ml with complete media (RPMI 1640, 10%
FCS, 1% gentamycin, and 5% IL-2) and transferred to a T-25 tis-
sue culture flask. On days 2, 4, 6, and 8 after infection, the cells
were pelleted, the media was replaced, and day 6 and 8 culture
supernatants were tested for p24 and RT activity, filtered through
a 0.45-mm filter, vialed as 1.0-ml aliquots, and stored at 
 
 
 
70
 
 
 
C
before infection of macrophages.
In indicated experiments, macrophages were pretreated for 1 h
with 25 
 
 
 
g/ml rabbit anti–annexin II (Santa Cruz Biotechnology,
Inc.), 25 
 
 
 
g/ml rabbit IgG (Jackson ImmunoResearch Laborato-
ries), or 10 
 
 
 
g/ml SLPI before the addition of virus. Alternatively,
the HIV-1 was preincubated with 10 
 
 
 
g/ml annexin II tetramer
(US Biological) for 1 h before being added to the macrophages.
After HIV-1 coculture for 2 h, virus and/or added reagents were
removed by washing cells with DMEM and fresh complete me-
dium was added. For cell-binding experiments, macrophages were
treated with anti–annexin II, control antibody, or SLPI for 30
min, washed, and virus was added for 30 min at 37
 
 
 
C. The cells
were washed extensively, lysed (0.5% Triton X-100 in PBS), and
p24 bound to the cells quantitated by ELISA. For infection of elu-
triated T cells, PHA-blasted T cells were infected with HIV-1
IIIB (Advanced Biotechnologies Inc.) for 2 h, washed, cultured
for 2–8 d, and supernatants were collected every 2–3 d for p24
ELISA. In some experiments, T cells were pretreated with rabbit
anti–annexin II or rabbit IgG before infection.
 
Cell-free Binding Assay.
 
96-well plates (Nunc immunoplates
with maxiSorp surface; Nunc) were coated with 60 
 
 
 
g/ml BSA
(Sigma-Aldrich), annexin II tetramer, IgG, or gp120 (NIH AIDS
Research and Reference Reagent Program) overnight at 4
 
 
 
C,
washed with PBS, and blocked or not with 1% BSA for 1–2 h.
After two PBS washes, 100 
 
 
 
l HIV-1
 
BaL 
 
(10
 
4
 
/ml) was added for
1 h at 4
 
 
 
C (3). After multiple washes with PBS, 100 
 
 
 
l of lysis
buffer (0.5% Triton X-100) was added. Virus was quantified by
p24 ELISA.
 
PCR for Viral DNA.
 
For a PCR-based assay for newly syn-
thesized viral DNA (3), 200 
 
 
 
l of DNase-treated HIV-1
 
BaL 
 
(10
 
4
 
/
ml) was added to macrophages preincubated with anti–annexin II
or control antibody for 30–60 min at 37
 
 
 
C. After 2 h of cocul-
ture, the cells were washed three times with PBS, treated with
trypsin-EDTA (0.05% trypsin and 0.53 mmol/l EDTA for 5 min
at 24
 
 
 
C) to remove noninternalized virus particles, washed twice
with DMEM and 10% FCS, and incubated for 18–36 h. Cells
were then washed, harvested in lysis buffer (100 mmol/l KCl, 10
mmol/l Tris HCl, pH 8.0, 2.5 mmol/l MgCl
 
2
 
, 0.5% Tween 20,
and 0.5% NP-40), and 1 
 
 
 
g of DNA was subjected to nested
primer PCR amplification (25 
 
 
 
l total volume). The first 35-
cycle round of amplification used primers corresponding to the
env gene (nucleotide 8838 to 8358, HIV-1HXB2 sequence) and
the U3 region of the 3
 
  
 
long terminal repeat (nucleotide 9533 to
9558). Each cycle consisted of denaturation for 1 min at 94
 
 
 
C,
annealing for 1 min at 55
 
 
 
C, and elongation for 1 min at 72
 
 
 
C.
PCR reactions (2.5 
 
 
 
l each) from the first amplification were
then subjected to a second 30-cycle amplification round using
primers (5
 
  
 
primer, nucleotide 8754 to 8782; 3
 
  
 
primer, nucle-
otide 9436 to 9457) located within the nef gene. PCR products
(
 
 
 
730 bp) from the second amplification were visualized by
ethidium bromide staining after agarose gel electrophoresis.
 
Results
 
SLPI Membrane Binding.
 
In previous studies (3), we
documented that 
 
125
 
I-rhSLPI binds to human monocyte–
derived macrophages in a specific, concentration-depen-
dent, and saturable manner. In the current studies, SLPI
binding was detected on SLPI-treated human monocytes
and macrophages with anti-SLPI antibody or using 1 
 
 
 
g/
ml of a biotinylated rhSLPI and streptavidin-FITC with
enhanced sensitivity. Direct binding of SLPI to macro-
phage membranes was detected in 
 
 
 
85% of macrophages
by flow cytometry (Fig. 1 A). By fluorescence microscopy,
cell surface rhSLPI–biotin–neutravidin–FITC complexes
were evident within 1 min, peaked at 15–30 min (Fig. 1
B), and frequently appeared to polarize before emerging in
the cytosol, all consistent with a cell membrane–binding
molecule/receptor.
Identification of the SLPI Membrane–binding Protein. To
identify such a receptor, macrophage membrane proteins
were isolated and SLPI immunoprecipitates were sub-
jected to SDS-PAGE. RhSLPI reproducibly coimmuno-
precipitated with protein bands at 36 and  42 kD (Fig. 2
A), which, being similar to previously described binding
activity (3), were selected for further analysis. After in-gel
tryptic digestion of these bands, the resultant peptides
were analyzed by LC-MS/MS and database searching
(SEQUEST; Wistar Institute) revealed annexin II as the
p36 SLPI–binding partner/receptor. Annexin II was con-
firmed with monoclonal anti–annexin II and rhSLPI co-
immunoprecipitation followed by Western blotting (Fig.
2, B and C). The p42 SLPI–binding protein band wasSLPI Targets Annexin II, an HIV-1 Cofactor 1340
identified by mass spectrometry as actin, which we deter-
mined does not interact with rhSLPI directly, but rather
associates with annexin II as part of a trimolecular com-
plex (not depicted).
The detected binding between annexin II and rhSLPI
was typically higher on differentiated macrophages than on
freshly isolated blood monocytes or an undifferentiated
monocytic cell line (Fig. 2 C, U937), consistent with label-
ing studies and with PCR analysis (Fig. 3 A) of annexin II
mRNA expression in these populations. Although annexin
II protein was not detected in lysates of a T cell line (Fig. 2
C, Jurkat), it was evident in epithelial cell lysates (Fig. 2 C,
A431). Importantly, assessment of annexin II on CD4 
blood mononuclear cells revealed differential membrane
expression between freshly isolated resting CD4  T cells
and CD14  monocytes (Fig. 3, B and C). The absence of
fluorescence staining of annexin II on CD4  T cells was
confirmed by their lack of detectable annexin II membrane
protein by Western blot (Fig. 3 D). Collectively, these data
identify mononuclear phagocytes as the predominant pop-
ulation expressing the SLPI membrane–binding protein,
annexin II.
Annexin II Is a Cofactor for HIV Infection. Based on the
link between SLPI, a known antagonist of HIV-1 infection
(2, 3), and annexin II, we attempted to abort infection by
directly blocking annexin II. A single treatment of adherent
macrophages with an antibody targeting the NH2-terminal
tail of annexin II (Fig. 4, A and B), but not the carboxy ter-
minus (not depicted) nor an IgG isotype control (Fig. 4 B),
during the initial infection process resulted in significant
( 90%) and durable ( 14 d) suppression of R5 HIV-1BaL
infection. Infection was monitored by HIV-1 p24 antigen
levels (Fig. 4) and by ultrastructural evidence of viral repli-
cation (not depicted). Furthermore, decreased expression of
annexin II using RNA-mediated interference (RNAi; Fig.
4 C, inset) dramatically suppressed macrophage viral infec-
tion (Fig. 4 C). Although suppression of annexin II protein
by RNAi was not absolute, likely related to inability to
transfect all cells and/or due to stability of intracellular an-
nexin II, the reduced levels of annexin II were sufficient to
interrupt the HIV-1 infection process, with the implication
that there might be a threshold level of annexin II necessary
for optimal infection. Furthermore, to establish that the
suppression of viral infection was specific to annexin II lev-
els, we monitored the macrophages treated with annexin II
Figure 1. SLPI membrane binding. (A) FACS histogram depicting
macrophage surface biotinylated rhSLPI detected with streptavidin-FITC
fluorescence (shaded curve). Left curve represents staining with streptavidin-
FITC only. A representative experiment (n   8) is shown. (B and C) Detec-
tion of biotinylated SLPI binding with neutravidin-FITC (green; 15 min)
on macrophages by fluorescence microscopy with propidium iodide
counterstain (red) of cells after fixation (B) or propidium iodide counter-
stain only (C).
Figure 2. SLPI membrane–binding protein identification by LC-MS/
MS. (A) Macrophage membrane proteins from coimmunoprecipitation
(SLPI/anti-SLPI; pooled donors) were separated on SDS–PAGE in Tris-
glycine gels under reducing conditions. The arrows indicate bands analyzed
with LC-MS/MS after in-gel tryptic digests for sequencing and database
searching. (B) The 36-kD protein band was identified as annexin II and
confirmed as the SLPI-binding molecule by coimmunoprecipitation of
rhSLPI and anti–annexin II. Western blots were probed with anti–annexin II
or anti-SLPI in monocytes and macrophages. (C) SLPI coimmunoprecip-
itated with annexin II on monocytes and macrophages, but not on a
monocytic cell line (U937). Annexin II was detected in whole cell lysates
of epithelial (A431), but not T cell (Jurkat), lines.Ma et al. 1341
RNAi for CD4 and CCR5 expression in parallel. As evi-
dent by Western analysis (Fig. 4 D) and by flow cytometry
(not depicted), no substantive change in these essential viral
recognition and binding receptors was evident, consistent
with a contributing role for annexin II in the macrophage
infection process.
To determine whether annexin II played a role in infec-
tion of macrophages by viral isolates other than the labora-
tory-adapted BaL strain, macrophages were treated with an
antibody to annexin II at the time of infection with two ad-
ditional laboratory-adapted M tropic isolates (ADA and
JRCSF) and a primary clinical isolate (Clade B 92US712).
As evident in Fig. 4 E, by blocking access to annexin II with
an annexin II–specific antibody, infection by all three viral
strains was dramatically inhibited, paralleling the effect seen
with BaL and underscoring the contribution of annexin II
to the macrophage infection process. Moreover, in CD4  T
cell infection with IIIB, antibodies to annexin II were not
effective in blocking the virus (Fig. 4 F). In additional stud-
ies to establish whether annexin II represented a pathway
unique to HIV-1 or supported infection with other viruses,
we determined in preliminary experiments that annexin II
appears to play no role in infection of cells with either Ebola
virus or with SARS coronavirus (not depicted). Thus, an-
nexin II appears to selectively contribute to the pathway by
which HIV-1 infects human macrophages.
Annexin II Interacts with PS. How annexin II might
support HIV-1 infection of macrophages was a mystery,
but a recent study reporting that HIV-1 membranes con-
tain PS (14) provided a potential clue. Although no bind-
ing partner for HIV-PS had been identified, we surmised
that annexin II, a phospholipid-binding protein, might be a
candidate. In this regard, direct binding of HIV-1 to plate-
bound annexin II, but not irrelevant proteins, was demon-
strated (Fig. 5 A). Moreover, to verify an HIV-PS–macro-
phage annexin II connection, we exposed HIV-1 to excess
soluble annexin II to bind/coat viral PS before addition to
macrophages, and this markedly suppressed subsequent in-
Figure 3. Monocytes and macrophages differentially express annexin II. (A) By RT-PCR, annexin II mRNA expression was higher in macrophages
than freshly isolated blood monocytes (representative RT-PCR shown; graph represents mean   SD; n   3; *, P   0.002). (B and C) By flow cytometry,
purified CD4  CD14  monocytes expressed surface annexin II, with minimal expression on CD4  T cells. Shaded histograms represent annexin II fluo-
rescence and white histograms represent cells stained with the isotype control antibody. (D) By coimmunoprecipitation and Western analysis, annexin II
was detected in macrophage, but not T cell, membrane preparations.SLPI Targets Annexin II, an HIV-1 Cofactor 1342
fection (Fig. 5 B), compatible with inhibition of infection
by soluble annexin V and/or PS vesicles (14).
Annexin II Is Associated with Entry/Fusion of HIV-1 in
Macrophages. Next, we focused on when in the virus life
cycle annexin II cooperates with HIV-1 to promote infec-
tion. Consistent with SLPI (2, 3), blockade of annexin II on
macrophages did not significantly interrupt HIV-1 binding
to the cells (Fig. 5 C), likely dissociating it from a direct in-
teraction with CD4 and/or CCR5. In confirmatory studies,
anti–annexin II was incorporated into a fusion assay in
which effector cells expressing recombinant Env, but lack-
ing viral PS, were cocultured with target cells expressing re-
combinant CD4 and coreceptors (23). In the absence of PS,
anti–annexin II was ineffective in interrupting this fusion
process (not depicted), ruling out a specific interaction with
Env, CD4, and/or coreceptors. These data emphasize the
potential unique constraints of macrophage–HIV-1 entry
events that might be optimized through an annexin II–PS
cofactor linkage. Although the role of annexin II in viral
entry may involve participation in internalization or struc-
tural/functional facilitation of fusion events, it was unclear
whether membrane annexin II had intracellular access. Be-
cause apoptotic cells also bind through PS to annexin II on
macrophages (24, 25), we exposed macrophages to apop-
totic Jurkat cells (PS ) as a model of annexin II–dependent
internalization. By immunofluorescence, annexin II could
be found within the early phagosome membrane, consistent
with surface membrane internalization (Fig. 5 D). Whether
internalization is essential to viral entry is under investiga-
tion, but by multiple criteria, the role of annexin II appears
instrumental early in the infection process. To confirm that
disconnecting the HIV–annexin II bond inhibits the virus
Figure 4. Annexin II as a cofactor in HIV infection. (A) Adherent macrophages in 48-well plates were treated or not with 25  g/ml anti–annexin II
for 60 min at 37 C before infection with M tropic HIV-1BaL for 2 h, the unbound virus was washed away, and the cells were cultured in DMEM con-
taining 10% FCS. Every 2–3 d, aliquots of supernatants were removed, replaced with fresh medium, and tested for HIV-1 p24 antigen. (B) Macrophages,
treated or not with anti-annexin, IgG, or SLPI for 60 min, were infected with HIV-1 and 14-d supernatants were tested for p24. A representative exper-
iment (n   4) is shown. (C) SiRNA sequences 1, 2, and control (cSi) were transfected into monocytes using the Amaxa Nucleofector kit, in parallel with
an electroporation control (EP) and an untreated control (Ctrl). The cells were incubated 6 d before analysis of annexin protein by Western (inset) and
infection with HIV-1. Supernatants were assayed for HIV-1 p24 10 d after infection (n   5). (D) Macrophages treated with siRNA as indicated in C
were analyzed for annexin II, CD4, and CCR5 protein by Western blot. (E) Macrophages were treated with anti–annexin II, infected with HIV-1
JRCSF (JRC; TCID50   250/ml), ADA (TCID50   10,000/ml), or primary isolate Clade B 92US712 (TCID50   1,000/ml), washed, and cultured,
with supernatants collected for p24 ELISA every 2–3 d for 12 d. (F) PHA-blasted T cells were treated with anti–annexin II or isotype IgG before infec-
tion with T cell tropic HIV IIIB. P24 levels on day 7 are shown.Ma et al. 1343
life cycle after HIV-1 binding but before reverse transcrip-
tion, as shown for SLPI (3), macrophages were infected
with or without annexin II inhibitors and the formation of
nascent viral DNA was assessed using a nested PCR-based
assay. The presence of anti–annexin II during the initial vi-
rus inoculation period dramatically inhibited subsequent vi-
ral DNA synthesis, as demonstrated by the HIV-1–specific
730-bp PCR product (Fig. 5 E), even though annexin II
blockade did not disengage the viral-binding step (Fig. 5 C).
Collectively, these data indicate that interference with mac-
rophage membrane annexin II inhibits infectivity after bind-
ing, but pre-reverse transcription, consistent with a strangle-
hold on the viral entry/fusion step.
Discussion
In this study, we identify annexin II as a novel macro-
phage membrane–binding protein for the innate host de-
fense protein, SLPI, by multiple parameters including im-
munoprecipitation, mass spectrometry, peptide sequencing,
and binding specificity. Striking was the ability of inhibitors
of annexin II to mimic the kinetics and apparent mecha-
nism of HIV-1 suppression by SLPI, denoting a shared site
of action. Although not ruling out additional binding tar-
gets for SLPI, annexin II appears to be significant in medi-
ating its anti–HIV-1 activity. Subsequent to binding of
HIV-1 to the canonical receptors, CD4 and CCR5, HIV-1
fuses with the host cell membrane that might be facilitated
by viral envelope PS (14). PS is not encoded by HIV-1, but
rather is acquired from its host cell membrane as it exits the
cells (26). During viral assembly at the cell surface or within
cytoplasmic vesicles, cell membrane components become
incorporated into the new viral coat along with virally en-
coded gp120/gp41. The resulting mosaic HIV-1 envelope
represents a lipid bilayer with a unique cholesterol/phos-
pholipid composition, embracing viral and host molecules,
including PS. Although PS enhances infection, it does not
mediate initial binding of the virus to the target cells (14),
Figure 5. Virus binding to an-
nexin II. (A) Nunc immunoplates
were coated with the indicated
proteins overnight at 4 C, washed,
and 100  l HIV-1 (104/ml) was
added for 1 h at 4 C. After six
PBS washes, adherent virions
were lysed and p24 was mea-
sured. Data represent mean and
SEM (n     2). (B) HIV-1 was
preincubated with excess soluble
annexin II tetramer for 1 h before
addition to macrophage cultures.
After 2 h of coculture, nonad-
herent virus was removed, mac-
rophages were cultured, and day
10 supernatants were assayed for
p24 levels. (C) After treatment
with anti–annexin II ( Ann II),
IgG, or SLPI for 30 min, macro-
phages were washed and HIVBaL
was added for 30 min at 37 C.
The cells were immediately
washed and lysed, and bound p24
was assayed by ELISA. (D) Con-
focal microscope images (mid-cell
single xy sections) of macrophages
and apoptotic Jurkat cells, fixed
10 min into the process of phago-
cytosis. Jurkat cells were stained
with the viable dye carboxyfluo-
rescein diacetate succinimidyl ester
(green) and macrophages were in-
cubated with mouse anti–annexin
II followed by Alexa 647–conju-
gated donkey anti–mouse second-
ary antibody (red), demonstrating
annexin II staining within the
phagosome membrane (arrows).
(E) Nested PCR detecting provi-
ral DNA on days 2 and 3 after
HIV-1 infection in macrophages
treated with DMEM (HIV), anti–
annexin II, or isotype control
IgG. Control represents unin-
fected cells.SLPI Targets Annexin II, an HIV-1 Cofactor 1344
consistent with our observations that neither soluble an-
nexin II, RNAi, anti–annexin II, nor the annexin II ligand,
SLPI, blocks HIV-1 binding, but rather inhibit postbinding
and pre-reverse transcription, a point in the viral life cycle
consistent with a proposed role for annexin II as a cellular
fusogenic cofactor.
Annexin II reportedly is found in caveolae and lipid rafts
in association with cholesterol (27) and mediates interac-
tions between cholesterol-rich membrane domains and the
actin cytoskeleton (28, 29), which may navigate HIV-1
through the labyrinth of the cell membrane. Our data favor
a model in which PS in the viral coat interacts with annexin
II on the surface of macrophages subsequent to recognition-
specific gp120 interactions with CD4 and the chemokine
coreceptors that instigate coiled coil exposure of gp41 fu-
sion domains to interact with the lipid bilayer of the target
cell (10, 30), and then engage an annexin II–dependent fu-
sion/entry pathway leading to productive infection.
Annexin II may represent a molecular pathway exploited
by HIV-1 unique to macrophage hosts and thus, a potential
target to block their virus susceptibility. Both laboratory-
adapted and clinical M tropic isolates appear to coopt this
host cell bridge into the cell’s interior. Whether annexin II
selectively boosts the viral entry/fusion process or possibly
also influences pathways involved in HIV-1–mediated mac-
rophage signaling, viral DNA transport, or subsequent vi-
rion construction, budding and release remains to be deci-
phered. Annexin II has the potential to traverse into
intracellular compartments and interaction of annexin II
with the actin cytoskeleton may not only facilitate internal-
ization, but also the trafficking of HIV-1 within the cell
and/or represent the scaffolding for viral transcription (30).
Nonetheless, our data support a dominant role of annexin II
to be in the early steps of the infection process, preceding
reverse transcription. Annexin II may represent one of mul-
tiple potential cofactors, such as syndecan and human neu-
trophil elastase (31, 32), which independently or collabora-
tively might be usurped by HIV-1 to facilitate the infectious
process. Because annexin II is a membrane-associated pro-
tein, best known as a docking station for tissue plasminogen
activator/plasminogen (16), it is unclear if it transduces a
signal because it lacks a hydrophobic signal sequence, but
conceivably, may serve as an adaptor in a signaling cascade.
Annexin II can be phosphorylated at key residues by several
kinases, including the src oncogene (17) and Pyk-2 (15), a
tyrosine kinase activated by HIV-1 (33, 34), but such a
pathway awaits delineation. Although less persuasive due to
the temporal association of SLPI/anti–annexin II inhibition
with preintegration events, SLPI may also influence NF- B
activation and/or proteasome inhibition (6, 8), both of
which are requisite in an optimal infection process (35–37).
Whether the relative lack of abundance of annexin II on
the perimeter of immature blood monocytes compared
with mature macrophages influences their differential per-
missiveness to HIV-1 infection is of interest. A related, in-
triguing question is whether the viral tropism characteristic
of T cell and macrophage targets bears any association with
their divergent annexin II expression. Annexin II on mac-
rophages may preferentially facilitate entry of virions ex-
pressing PS acquired during exit from prior macrophage
hosts or from T cells undergoing apoptosis that only then
express PS on their outer membrane leaflet (38, 39), as
compared with virions budded from PS-less viable T cells.
R5 viruses mediate both mucosal and blood-borne trans-
mission of HIV-1 infection, whereas the X4 (T tropic) vi-
ruses typically abound in the later stages of disease during
clinical progression to AIDS (11, 40, 41). Moreover, when
infected T cells succumb to apoptosis, recognition of their
newly exposed PS will promote clearance by annexin II–
bearing macrophages with the potential for HIV-1 transfer
(42). It is conceivable that PS–annexin II interactions in the
cytoplasmic vesicles and late endosomes of macrophages,
where structural assembly of virions occurs (12, 43) and an-
nexin II is found (28), not only serve as a construction scaf-
folding, but also as a tether to retain virions intracellularly
in a covert maneuver to avoid detection at the cell surface.
Because the S100A10 component of the annexin II com-
plex has been shown to facilitate arbovirus exocytosis (44),
such a role in HIV-1 egress might also be considered. An-
nexin II/PS may also contribute to the host cell–derived
cloak of the hypothetical Trojan exosomes that subver-
sively deliver retroviral particles to nearby cells (45), thus a
co-conspirator with HIV-1 both going in and coming out.
The identification of a novel role for annexin II as a cel-
lular cofactor in HIV-1 entry/fusion has implications for
specific antiviral strategies, albeit primarily targeting macro-
phage infection. Nonetheless, as macrophages may contrib-
ute to initial viral selection, dissemination, and transmission
of virus to CD4  T cells, and serve as long-term covert res-
ervoirs of HIV-1 (11, 40, 46), this would be an enviable
goal. Particularly evident is the enormous viral burden in
macrophages in later stage HIV-1/AIDS during opportunis-
tic infections (12, 21, 22). Further unraveling of the com-
plex interplay between viral envelope and macrophage
membrane constituents remains crucial to the development
of antiviral agents active before permanent viral integration
into the host cell genome when the virus is most vulnerable.
The persistence of HIV-1 infection, coupled with its in-
credible mutation rate and insular reservoirs, focuses atten-
tion on host cell constituents usurped by the virus as poten-
tial intervention targets. In this regard, annexin II, a host cell
molecule that the virus has appropriated for easing its en-
trance into the host cell, represents a likely candidate, and
SLPI, an endogenous ligand for annexin II, or other an-
nexin II–specific blockades, may represent a therapeutic im-
pediment to the infection process. Clearly, viral pathogens
other than HIV-1, including CMV and respiratory syncytial
virus (19, 20), also take advantage of target cell annexin II to
enhance their infectivity and/or dissemination, and further-
more, bacteria trigger annexin II recruitment to their at-
tachment sites (27), all suggesting its broader involvement in
microbial entrance and pathogenesis.
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